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I M M U N O L O G Y
Endogenous DEL-1 restrains melanoma lung metastasis 
by limiting myeloid cell–associated lung inflammation
Young-Min Hyun1*, Sang-Uk Seo2,3*, Woo Seon Choi4,5, Hyung-Joon Kwon4, Dong-Young Kim4, 
Soi Jeong1, Gyeong-Yi Kang1, Eunbi Yi4,5, Minjung Kim4, Hyun Jin Ryu4, Mark R. Looney6, 
Eun Young Choi4†, Hun Sik Kim4,5†
Distant metastasis represents the primary cause of cancer-associated death. Pulmonary metastasis is most fre-
quently seen in many cancers, largely driven by lung inflammation. Components from primary tumor or recruited 
leukocytes are known to facilitate metastasis formation. However, contribution of target site–specific host factor 
to metastasis is poorly understood. Here, we show that developmental endothelial locus–1 (DEL-1), an anti- 
inflammatory factor abundant in the lung and down-regulated by inflammatory insults, protects from melanoma 
lung metastasis independently of primary tumor development and systemic immunosurveillance. DEL-1 
deficiency is associated with gene profiles that favor metastatic progression with inflammation and defective 
immunosurveillance. Mechanistically, DEL-1 deficiency primarily influences Ly6G+ neutrophil accumulation in 
lung metastatic niche, leading to IL-17A up-regulation from  T cells and reduced antimetastatic NK cells. In support, 
neutrophil depletion or recombinant DEL-1 treatment profoundly reverses these effects. Thus, our results identify 
DEL-1 as a previously unrecognized link between tumor-induced inflammation and pulmonary metastasis.
INTRODUCTION
Metastatic tumors originating from malignant primary tumors are 
the leading cause of cancer-related mortality (~90%). Metastasis 
comprises a stepwise cascade encompassing the invasion and dis-
semination of the malignant cells followed by their colonization and 
adaptation to the microenvironment of the metastatic site. In these 
processes, an important determinant is tumor cell interactions with 
the host microenvironments, affecting host cell composition, cytokine 
milieu, and extracellular matrix (ECM) structures (1). In particular, 
distant metastasis to the target organ requires establishment of a favor-
able local microenvironment, termed the (pre)metastatic niche, for 
efficient colonization of the metastatic cells and their outgrowth (1, 2). 
The contribution of various tumor-derived factors, consequent re-
cruitment of bone marrow–derived cells (BMDCs), underlying ECM 
remodeling, and inflammation to metastatic niche formation is well 
documented (2–4). However, relatively little is known about target 
organ–specific host factors that contribute to shaping the metastatic 
microenvironment. This study would provide an important insight 
into metastatic niche formation and organ-specific metastatic tro-
pism, which remains one of the key unresolved questions in cancer 
research (2, 5).
Developmental endothelial locus–1 (DEL-1) is a secretory glyco-
protein that is predominantly expressed by vascular endothelial cells 
in the lung and the brain and associates with the cell surface and the 
ECM (6, 7). DEL-1 is also known as epidermal growth factor (EGF)–
like repeats and discoidin I–like domains 3 (EDIL3) by virtue of its 
three N-terminal EGF-like repeats and two C-terminal discoidin 
I-like domains. DEL-1 interacts with phospholipids and distinct in-
tegrins, including L2 (LFA-1; CD11a/CD18) and M2 (Mac-1; 
CD11b/CD18) that are crucial to leukocyte adhesion, transmigra-
tion, and intraluminal crawling on the endothelium (6, 8, 9). Consistent 
with these characteristics, endothelial DEL-1 has recently emerged 
as a critical tissue homeostatic factor that regulates local inflammation 
by interfering with 2 integrin–dependent recruitment of leukocytes, 
predominantly neutrophils, to peripheral tissues (6). DEL-1–deficient 
mice exhibit an increased leukocyte infiltration and inflammatory 
pathologies in preclinical models of pulmonary inflammation and 
fibrosis (7, 10). DEL-1 deficiency also aggravates disease severity of 
experimental autoimmune encephalomyelitis and inflammatory bone 
loss, accompanied by up-regulation of interleukin-17 (IL-17) and 
neutrophil infiltration (11, 12). Given a causal link between inflam-
mation and tumor progression, and being a regulator of local in-
flammation, it is feasible that tissue-derived DEL-1 modulates cancer 
metastasis. However, this possibility of metastasis control by local 
inflammatory regulator has not yet been addressed.
Among other organs with prominent DEL-1 expression, the lung 
is susceptible to inflammatory insults (13) and is a frequent metastatic 
site for different types of cancer, including melanoma, breast can-
cer, and lung cancer itself (14). Of particular interest is melanoma 
metastasis to the lung, given the preferential metastasis of lung-homing 
melanoma cells (15) and the strong association between inflammation 
and melanoma lung metastasis (16). DEL-1 has been recently impli-
cated in primary tumor progression in a tumor cell–autonomous 
manner (17–19). These studies have centered on tumor-derived 
DEL-1 in certain cancer types and its potential contribution to pro-
liferation, survival, and invasion of the cancer cells, using in vitro 
culture and an immunodeficient mouse model, without the assess-
ment of tumor-host interactions. Thus, we sought to study the role 
of host DEL-1 in the formation of melanoma lung metastasis using 
syngeneic mouse models, focusing on immune cells in the metastatic 
niche that govern the balance between tumor escape versus elim-
ination and thereby dictate metastatic outgrowth.
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RESULTS
DEL-1 deficiency aggravates lung metastasis but not 
primary melanoma growth
To study the effects of DEL-1 on melanoma lung metastasis, we used 
an experimental metastasis model of B16F10 melanoma cells. B16F10 
cells injected via the tail vein primarily colonize the lung and develop 
metastatic foci within 2 weeks (20). B16F10 cells were labeled with 
DsRed to allow a sensitive and quantitative assessment of metastatic 
spread by means of fluorescence intensity (FLI) (fig. S1A). DEL-1–
sufficient [wild-type (WT)] or –deficient (Del1KO) mice were then 
intravenously administered with the melanoma cells followed by the 
analysis of pulmonary metastatic growth. We found that Del1KO 
mice exhibited significantly more lung metastases than WT litter-
mates, as measured by metastatic foci formation and fluorescence 
imaging (Fig. 1, A and B). Consistent with these findings, histologic 
examination of the lungs revealed increased nodule size and frequency 
of macrometastases (>1-mm diameter) in Del1KO mice (Fig. 1, 
C to E), suggesting more severe metastatic growth with DEL-1 defi-
ciency. Similar results were also obtained at a lower tumor dose; 
Del1KO mice showed a significant increase in lung, but not liver, 
metastasis compared with WT mice (fig. S1, B to E), supporting the 
regulation of lung metastasis by DEL-1.
We next sought to determine whether DEL-1 also regulates the 
development of tumors at the orthotopic site. To this end, B16F10 
cells expressing DsRed were implanted in the skin of the mice. 
There was no significant difference in the growth and weight of primary 
tumors over 3 weeks in Del1KO mice compared with WT mice (Fig. 1, 
F and G). However, a significant increase in spontaneous metastasis 
to the lung 3 weeks after inoculation, a time point of detectable mela-
noma seeding (4), was observed in Del1KO mice compared with WT 
mice (Fig. 1, H and I). This observation indicated that DEL-1 restrains 
melanoma lung metastasis but not primary tumor growth.
It has become clear that metastatic dissemination of tumor cells 
depends on escape from host immune surveillance (21). B16F10 
melanoma cells are deficient in major histocompatibility complex 
(MHC) class I surface expression, as confirmed here (fig. S2A), and 
are preferentially targeted by natural killer (NK) cells that exert robust 
control on metastatic dissemination (22). Consistent with previous 
studies (23, 24), systemic metastasis of B16F10 cells was mainly under 
the control of NK cells, as demonstrated by a substantial increase in 
Fig. 1. Melanoma metastasis to the lung but not primary tumor growth is DEL-1 dependent. (A to E) WT (n = 10) or Del1KO (n = 13) mice were injected intravenous-
ly with 5 × 105 DsRed-B16F10 cells and analyzed for lung metastasis after 2 weeks. (A) Representative lung images (top) and corresponding DsRed fluorescence images 
(bottom). (B) Quantification of lung metastases by FLI depicted in (A). (C) Representative hematoxylin and eosin–stained lungs and (D) quantification of metastatic nodule 
size and (F) macrometastases from mice in (A). (F to I) DsRed-B16F10 cells were injected subcutaneously into WT and Del1KO mice (n = 6 per group). (F) Tumor sizes and 
(G) tumor weights were determined at the indicated time points and on day 21, respectively. (H) Representative lung images (top) and corresponding fluorescence im-
ages (bottom) showing spontaneous lung metastases. (I) Quantification of lung metastases by FLI depicted in (H). (J and K) Natural killer (NK) cell–mediated lymphoma 
clearance assay (n = 5 per group) showing representative result (J) and graph (K). (L and M) NK cell degranulation assay (n = 6 per group) showing representative result (L) 
and graph (M). *P < 0.05; **P < 0.01. Photo credits for (A) and (H): Hyung-Joon Kwon, University of Ulsan.
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lung metastasis formation following NK cell depletion with anti–
asialo-GM1 antibody but not CD4 or CD8 T cell depletion (fig. S2, 
B to E). NK cell depletion was also associated with an increase in 
liver metastasis (fig. S2, F and G), distinct from the effect of DEL-1 
deficiency (fig. S1, D and E).
Thus, we studied whether DEL-1 deficiency is associated with an 
intrinsic defect in NK cell effector function. To assess systemic cy-
tolytic activity of NK cells in vivo, we used a syngeneic lymphoma 
clearance model in which NK cells selectively kill MHC class I– 
deficient RMA-s cells over their parent MHC class I–intact RMA 
cells (25). We labeled RMA-s and RMA cells with high and low con-
centrations of carboxyfluorescein succinimidyl ester (CFSE) dye, 
respectively, and then coinjected equal numbers of the cells intra-
peritoneally into mice. Selective clearance of RMA-s cells over RMA 
cells was evident and comparable between WT and Del1KO mice 
(Fig. 1, J and K). Supporting the in vivo results, DEL-1 deficiency 
did not affect the cytolytic capacity of splenic NK cells against B16F10 
(Fig. 1, L and M) or YAC-1 target cells (fig. S3, A and B). Moreover, 
DEL-1 deficiency had no effect on the cytotoxic activity of CD8 
T cells upon stimulation with anti-CD3 antibody (fig. S3, C and D).
Given the prominent expression of DEL-1 in the endothelial 
barrier of the lung, these results suggest that DEL-1 deficiency has a 
localized effect on the control of lung metastasis that is independent 
of systemic immune surveillance.
DEL-1 deficiency affects gene expression profiles linked 
to inflammation and tumor immunity
To gain insight into pathogenetic mechanisms underlying the role 
of DEL-1 in metastasis, we next assessed the gene expression profile 
of the lung tissue of metastatic tumor-bearing mice. We focused on 
the tumor immune microenvironment using a polymerase chain 
reaction (PCR) array of 84 key genes associated with cancer inflam-
mation and immunity cross-talk. Differentially expressed genes were 
identified as those up- or down-regulated by >2-fold in Del1KO 
mice compared with WT mice. Our analyses revealed that DEL-1 
deficiency caused significant changes in several mediators and ef-
fectors of cross-talk between tumors and the immune system in the 
metastasis-bearing lung. DEL-1 deficiency was associated with an 
increased expression of genes related to tumor progression and metas-
tasis (Aicda, Hif1a, Bcl2l1, and Myc), which correlated with down- 
regulation of genes involved in antitumor immunity (fig. S4). In line 
with these findings, similar decreases in expression were observed 
for genes encoding granzyme B (Gzmb; 1.9-fold), interferon- (Ifng; 
1.91-fold), and its downstream targets (Stat1; 1.9-fold and Gbp2b). 
Of particular note was the increased expression in the gene encoding 
the p19 subunit of IL-23 (Il23a; 2.27-fold), which is linked to tumor- 
promoting chronic inflammation and suppression of tumor immune 
surveillance (24). Furthermore, there was an increase in gene expres-
sion (Ccr1, Cxcr1, and Cxcr2) related to the accumulation of tumor- 
associated myeloid cells that help establish an immunosuppressive 
microenvironment (26, 27). Together with an intact immune surveil-
lance by DEL-1–deficient NK cells, these results raise the possibility that 
DEL-1 deficiency may contribute to lung metastatic niche formation 
involving dysregulation of local immune homeostasis and inflammation.
DEL-1 deficiency leads to dysregulation of lung immune 
and inflammatory cell landscape
Having observed altered expression of genes encoding chemokine 
receptors, we evaluated whether DEL-1 deficiency could affect im-
mune cell infiltration. Flow cytometry was used to analyze different 
leukocyte populations in the metastatic lung of WT and Del1KO mice 
(fig. S5). We found that the proportion of neutrophils, defined as 
CD45+CD11b+Ly6G+Ly6Cint and known to support metastatic pro-
gression (28, 29), was significantly elevated in the metastasis-bearing 
lungs of Del1KO mice (Fig. 2, A and B) but not in the lungs of control 
tumor-free mice (fig. S6, A and B). These findings are compatible with 
the role of DEL-1 in the recruitment of neutrophils in inflammation- 
associated pathologies (6). By contrast, DEL-1 deficiency did not 
affect the infiltration of CD11b+Ly6G−Ly6C+ monocytes, CD11c+F4/ 
80−MHCII+ dendritic cells, or CD11b+F4/80+MHCII+ M1-like and 
CD11b+F4/80+CD206+ M2-like macrophages among the CD45+ cell 
populations. CD3−NK1.1+ NK cells that prevent B16F10 lung me-
tastasis, but not other lymphocytes including CD4+ T cells, CD8+ 
T cells, and  T cells, were significantly decreased by DEL-1 defi-
ciency (Fig. 2, A and B). These findings were supported by immu-
nofluorescence analysis, which revealed a marked increase in the 
infiltration of Ly6G+ neutrophils in the metastatic lungs of Del1KO 
mice, particularly at the peritumoral region, along with decreased 
infiltration of NK1.1+ NK cells (Fig. 2C). Murine NK cells acquire 
effector function through a three-stage maturation program, which can 
be defined by differential surface expression of CD11b and CD27 
(CD11b−CD27+, CD11b+CD27+, and fully mature CD11b+CD27−) 
(30). We observed a comparable frequency of all these subsets in 
metastasis-bearing lungs of WT and Del1KO mice, suggesting that 
functional NK cell maturation was not affected by DEL-1 deficiency 
(Fig. 2, D and E). Furthermore, there was no significant difference 
in the frequency of leukocyte populations, particularly neutrophils, 
in the spleen, liver, and peripheral blood, all absent in DEL-1 ex-
pression (7), between WT and Del1KO mice bearing B16F10 lung 
metastases (fig. S6, C to H). These findings provide further evidence 
for a preferential effect of DEL-1 on the recruitment of leukocytes to 
the lung of tumor-bearing mice.
DEL-1 deficiency promotes melanoma metastasis to the lung 
in a neutrophil-dependent manner
Next, we assessed whether the increased neutrophils were functionally 
important in melanoma lung metastasis of Del1KO mice. Neutrophils 
were depleted using anti-Ly6G antibody before and after intravenous 
injection of B16F10 cells expressing DsRed. We found that lung 
metastasis was significantly decreased by Ly6G+ neutrophil depletion, 
as assessed by metastatic foci formation and fluorescence imaging 
(Fig. 3, A and B). Efficacy of neutrophil depletion was confirmed in 
the lungs of treated mice (Fig. 3, C and D). This depletion led to a 
significant accumulation of NK cells, along with Ly6C+ monocytes. 
In addition, we observed an increase in mature cytotoxic NK cells 
(CD11b+CD27−) but a decrease in immature NK cells (CD11b−CD27+) 
(Fig. 3, E and F). Thus, these results suggest a negative regulation of 
NK cell homeostasis by neutrophils in the metastasis-bearing lung, 
an observation compatible with the prometastatic role of neutrophils 
via suppression of NK cell–mediated tumor cell clearance (31).
We then investigated the possible mechanisms underlying the 
increased neutrophil accumulation associated with lung metastasis 
in Del1KO mice. DEL-1 deficiency has been linked to enhanced 
lymphocyte production of IL-17 (11, 12), a cytokine that promotes 
neutrophil mobilization and expansion (27). IL-23, where we found 
the mRNA up-regulation of its subunit in the metastasis-bearing lungs 
of Del1KO mice (fig. S4), enhances IL-17 production in CD4+ T cells 
and  T cells (32). In support, IL-17A expression was significantly 
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increased by  T cells but not CD4+ or CD8+ T cells in the metastasis- 
bearing lungs of Del1KO mice (Fig. 3, G and H), and the increase 
was diminished by Ly6G+ neutrophil depletion (Fig. 3, I and J). 
These results support the clear link between IL-17–producing  
T cells and neutrophils in the tumor context (29, 33). To further 
probe the role of IL-17 in neutrophil accumulation and melanoma 
metastasis to the lung, mice were administered recombinant IL-17A 
during lung metastasis formation. IL-17A–treated mice exhibited a 
significant increase in the number of metastatic foci in the lungs, 
which was comparable to that of Del1KO mice (fig. S7A). Further-
more, immunohistochemical analysis revealed diminished DEL-1 
expression in the lungs, particularly in the vasculature, along with 
Ly6G+ neutrophil accumulation (fig. S7, B and C), which was consistent 
with IL-17–mediated repression of DEL-1 expression (34). Moreover, 
it appeared that the expression of DEL-1 along with CD31 became 
gradually lost at the peritumoral region during metastatic progression 
in WT mice (fig. S7D), consistent with neutrophil accumulation at 
the peritumoral region (Fig. 2C and fig. S7C). These results suggest 
a potential link among tumor-induced inflammation, DEL-1 defi-
ciency, and neutrophil accumulation. This notion was further supported 
by the reduced mRNA expression of DEL-1 during metastasis for-
mation in the WT mice (fig. S7E). Collectively, our results suggest a 
protective role for DEL-1 in limiting neutrophil accumulation and 
thereby melanoma metastasis to the lung via an effect on IL-17+  
T cells.
Administration of Del-1-Fc ameliorates lung metastasis
To further probe the antimetastatic function of DEL-1, we assessed 
the effect of recombinant DEL-1 treatment on neutrophil accumu-
lation and lung metastasis. Del-1-Fc fusion protein has been shown 
Fig. 2. Reciprocal regulation of Ly6G+ neutrophils and NK cells by DEL-1 in the metastasis-bearing lung. (A and B) Representative (A) and quantitative (B) flow 
cytometric analysis of various myeloid cells (CD11b+Ly6G+ neutrophils, CD11b+Ly6C+, monocytes, CD11c+MHCII+ dendritic cells, and F4/80+MHCII+ M1-like and 
F4/80+CD206+ M2-like macrophages) and lymphocytes (CD3−NK1.1+ NK cells, CD3+ T cells, CD8+ T cells, and CD4+ T cells) among CD45+ cell populations in the 
metastasis-bearing lungs of WT and Del1KO mice (n = 10 each group) on day 14 after intravenous injection of B16F10 cells. (C) Representative immunofluorescence staining 
for Ly6G and NK1.1 in a metastasis-bearing lung from each group of mice depicted in (A). Ly6G+ (green) neutrophils and NK1.1+ (red) NK cells with 4′,6-diamidino- 2-
phenylindole (DAPI) counterstain (blue) are shown. Magnified images (right panel for each mouse group) show peritumoral localization of Ly6G+ neutrophils. Scale bars, 
100 m. (D and E) Representative (D) and quantitative (E) flow cytometric analyses of CD11b and CD27 expression on NK1.1+ NK cells in the metastasis-bearing lungs of 
WT and Del1KO mice (n = 10 each group) depicted in (A). Horizontal bars indicate the means (B and E). **P < 0.01.
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to circulate and reduce neutrophil-mediated inflammatory pathologies 
(11, 12). WT mice were treated intravenously on a regular basis with 
either Del-1-Fc or control-Fc during lung metastasis formation. 
Prophylactic administration of Del-1-Fc significantly attenuated 
melanoma lung metastasis (Fig. 4, A and B), accompanied by re-
duced neutrophil accumulation (Fig. 4, C and D). Del-1-Fc adminis-
tration after tumor inoculation also alleviated melanoma lung 
metastasis (fig. S8, A and B) and neutrophil accumulation (fig. S8, 
C and D), suggesting the effect of DEL-1 during metastasis formation. 
These results support the notion that DEL-1 has a protective role 
against metastatic progression.
DEL-1 regulates lung metastatic niche formation
We next sought to elucidate the steps in the metastatic cascade af-
fected by DEL-1 deficiency. Given that there was no difference in 
primary tumor growth between WT and Del1KO mice (Fig. 1, F and G), 
we focused on the post-intravasation steps of the metastatic cas-
cade. To this end, we used an experimental metastasis model to cir-
cumvent the confounding effects of primary tumor-associated sys-
temic as well as lung inflammation (2, 16, 35). To facilitate the 
identification of the inoculated B16F10 cells, they were labeled with 
XenoLight DiR fluorescent dye that enables in vivo imaging of cell 
homing. WT or Del1KO mice were then intravenously adminis-
tered with the labeled B16F10 cells followed by the analysis of their 
trapping in various organs. DEL-1 deficiency did not affect the 
numbers of B16F10 cells that extravasate or seed in different organs 
including the lung, when evaluated by FLI up to 24 hours (fig. S9). 
Thus, DEL-1 deficiency might contribute to enhanced colonization 
of metastatic cells after initial seeding, which relies on lung meta-
static niche.
Accordingly, we evaluated whether DEL-1 deficiency could af-
fect the survival and proliferation of disseminated tumor cells in the 
lung during metastasis formation. To facilitate B16F10 cell identifi-
cation, metastasis-bearing lungs were examined after intravenous 
Fig. 3. DEL-1 deficiency promotes melanoma lung metastasis in a neutrophil-dependent manner. (A) Representative lung images (top) and corresponding DsRed 
fluorescence images (bottom) showing the diminished metastases to the lungs of Del1KO mice (n = 5 per group) treated with anti-Ly6G antibody. Photo credit: Hyung-
Joon Kwon, University of Ulsan. (B) Quantification of lung metastases by FLI depicted in (A). (C and D) Representative (C) and quantitative (D) flow cytometric analysis of 
myeloid cells and lymphocytes, graphed on Ly6C by Ly6G and CD3 by NK1.1 dot plots, respectively, among CD45+ cell populations in the metastasis-bearing lungs de-
picted in (A). (E and F) Representative (E) and quantitative (F) flow cytometric analysis of CD11b and CD27 expression on NK1.1+ NK cells depicted in (A). (G and H) Repre-
sentative (G) and quantitative (H) flow cytometric analysis of intracellular IL-17A expression in different lymphocytes in the metastasis-bearing lung of WT and Del1KO 
mice (n = 6 per group). (I and J) Representative (I) and quantitative (J) flow cytometric analysis of intracellular IL-17A expression in different lymphocytes depicted in (A). 
Horizontal bars indicate the means (D, F, H, and J). *P < 0.05; **P < 0.01.
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injection of DsRed-tagged B16F10 cells. DEL-1 deficiency did not 
affect the proportion of proliferating B16F10 cells relative to total 
B16F10 cells, as demonstrated by the immunohistochemical staining 
for Ki67, a widely used proliferation marker (fig. S10A). By comparison, 
the percentage of TUNEL-positive apoptotic B16F10 cells was sig-
nificantly lower in metastasis-bearing lungs of Del1KO mice com-
pared with WT mice (fig. S10B). This decrease in cell death was further 
confirmed by flow cytometric analysis of DsRed-tagged B16F10 cells 
after LIVE/DEAD dye staining (fig. S10C) and was associated with 
an attenuated cytotoxicity of NK cells in the metastasis-bearing 
lungs of Del1KO mice (fig. S10D). Treatment of B16F10 cells with 
Del-1-Fc had no direct effect on their proliferation and survival (fig. S10, 
E and F). Thus, these results suggest an impaired NK cell–mediated 
clearance of B16F10 cells as a potential mechanism of aggravated 
metastatic burden by DEL-1 deficiency, consistent with a decrease 
in NK cells in the metastasis-bearing lungs of Del1KO mice (Fig. 2,  
A and B).
Given a local defect in NK cells linked to neutrophil accumulation 
in DEL-1–deficient lung metastatic niche, we speculated that DEL-1 
primarily affects neutrophils rather than NK cells. Thus, we investi-
gated the effect of DEL-1 on leukocyte recruitment at early metastatic 
time points. Metastatic tumors are able to induce BMDC recruitment 
to the sites targeted for metastasis to form a metastatic niche, sup-
portive of tumor cell colonization (4, 35). This phenomenon can be 
mimicked by the administration of tumor-conditioned medium (CM) 
alone without tumor cell inoculation (4). Thus, tumor-free mice 
were intravenously injected with cell-free CM derived from B16F10 
melanoma cells (Fig. 5A). Compared with WT mice, Del1KO mice 
showed a significant increase in the frequency of neutrophils, but 
not of monocytes or lymphocytes examined, in the CM-treated lungs 
(Fig. 5, B and C). This increased recruitment of neutrophils was not 
observed in the spleen (Fig. 5, D and E). Next, we asked whether 
CM pretreatment modulates metastatic outcome upon tumor inocu-
lation. Thus, we repeated the above experiment of CM treatment, 
followed by intravenous injection of luciferase-labeled B16F10 mel-
anoma cells. We observed a significant increase in lung metastasis, as 
measured by bioluminescence imaging (BLI), in CM-treated WT 
mice (Fig. 5, F and G), compatible with an increase of neutrophils in 
CM-treated lungs (Fig. 5, B and C) relative to control lungs (fig. S6, 
A and B) of WT mice and a previous study (4). In comparison, the 
same treatment had a less significant effect in Del1KO mice, sug-
gesting that the prometastatic effect of CM was likely compensated 
by DEL-1 deficiency–associated neutrophil accumulation in lung 
metastatic niche (Fig. 2, A and B). DEL-1–dependent local accu-
mulation of neutrophils was also observed in the lung, but not blood 
and BM, of mice following systemic treatment with granulocyte- 
macrophage colony-stimulating factor (GM-CSF) and IL-6 (fig. S11, 
A and B). These cytokines are involved in the expansion, mobilization, 
or recruitment of myeloid cells including prometastatic neutrophils 
to the tumor site (e.g., lung) (36–39). In addition, DEL-1 deficiency 
did not affect the in vitro expansion of myeloid cells upon treatment 
of BM cells with GM-CSF and IL-6 (fig. S11, C and D). Thus, our 
results collectively suggested that DEL-1 primarily regulates the ac-
cumulation of Ly6G+ prometastatic neutrophils in the lung metastatic 
niche that facilitates the metastatic progression.
DEL-1 limits the recruitment of neutrophils to lung 
metastatic foci
To better understand DEL-1–dependent neutrophil trafficking in 
lung metastasis, we examined the spatiotemporal dynamics of neu-
trophil recruitment to early metastatic foci via two-photon intravital 
imaging. LysM–green fluorescent protein (GFP) mice were used to 
enable visualization of neutrophils that express GFP brightly com-
pared with monocytes and thus are readily identified as clear GFP+ 
cells (40, 41). Moreover, it is known that more neutrophils than 
monocytes extravasate (42). The imaging experiments were per-
formed after formation of metastatic foci via intravenous injection 
of DsRed-B16F10 cells (Fig. 6A). Compared with WT mice, Del1KO 
mice showed a significant increase in the number of neutrophils 
extravasated into the lungs, particularly around metastatic foci 
(Fig. 6, B and C, and movie S1). Analysis of the neutrophil migration 
trajectory toward melanoma foci revealed that more neutrophils 
swarmed to the metastatic foci from the longer distance by DEL-1 
deficiency (Fig. 6D and movies S2 and S3). Supporting this, DEL-1 
deficiency was related to significantly higher velocity (Fig. 6E) and 
longer distance, termed displacement (Fig. 6F), of neutrophil mi-
gration toward metastatic foci. However, DEL-1 deficiency did not 
affect the movement trajectory, termed meandering index (Fig. 6G). 
The increased migration of neutrophils was associated with signifi-
cantly enhanced adhesion of neutrophils to the luminal side of blood 
vessels (fig. S12). This result is compatible with a previous study 
showing the increased firm adhesion of leukocytes to the blood vessels 
in Del1KO mice using intravital imaging of the dorsal skin (7). We 
next investigated whether the increased migration of neutrophils was 
attributed to DEL-1 deficiency in neutrophils. Specifically, WT and 
Del1KO neutrophils were labeled with CMTPX [4(or 5)-(4-(chloro-
methyl)benzamido)-2-(1,2,2,4,8,10,10,11-octamethyl-1,2,10,11- 
tetrahydropyrano[3,2-g:5,6-g’]diquinolin-13-ium-6-yl)benzoate] 
(red) and CMFDA (5-chloromethylfluorescein diacetate) (green), 
Fig. 4. Melanoma lung metastasis and neutrophil accumulation are amelio-
rated by Del-1-Fc administration. (A and B) C57BL/6 mice were treated with 
intravenous injection of control-Fc or Del-1-Fc 6 hours before an intravenous in-
jection of 2 × 105 B16F10 cells expressing DsRed and twice a week treatment thereafter. 
(A) Representative lung images (top) and the corresponding DsRed fluorescence 
images (bottom) showing lung metastases (n = 8 each group) after 14 days of tumor 
implantation. Photo credit: Hyung-Joon Kwon, University of Ulsan. (B) Quantification 
of lung metastases by FLI depicted in (A). (C and D) Representative (C) and quanti-
tative (D) flow cytometric analysis of different myeloid cells and lymphocytes, graphed 
on Ly6C by Ly6G and CD3 by NK1.1 dot plots, respectively, in the metastasis-bearing 
lungs depicted in (A). Horizontal bars indicate the means (D). *P < 0.05.
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respectively, or vice versa for their identification, and then equal 
numbers of cells were coinjected intravenously into the metastasis- 
bearing lungs of Del1KO mice. The analysis using two- photon 
intravital imaging revealed that the migration of WT neutrophils was 
comparable to that of Del1KO neutrophils (fig. S13, A and B, and 
movie S4). In support, DEL-1 deficiency in neutrophils did not af-
fect their adhesion to and transmigration through Del1KO endothe-
lial cells (fig. S13, C and D). Thus, these data suggest the role of 
DEL-1 in endothelial cells, but not neutrophils, in the regulation of 
neutrophil trafficking into the metastasis-bearing lung.
Furthermore, we performed three-dimensional (3D) imaging of 
metastasis-bearing lung after optical tissue clearing to enable the 
anatomical location of neutrophils and metastatic cells in tissues and 
blood vessels to be distinguished throughout the 3D structure of the 
lung. Analysis of 3D imaging revealed the metastatic foci to be mainly 
localized in the tissue and not in the blood vessels (Fig. 6H and 
movie S5). Furthermore, the number of extravasated neutrophils 
close to metastatic foci (<50 m), but not that of tumor-infiltrating 
neutrophils, was significantly increased by DEL-1 deficiency (Fig. 6, 
I and J, movie S6). Thus, our results collectively suggest that DEL-1 
deficiency promotes the recruitment of neutrophils into the lung to 
surround metastatic foci, possibly creating a permissive microenvi-
ronment for metastatic growth of disseminated tumor cells.
DISCUSSION
The lung is a frequent site of metastatic colonization from diverse 
extrapulmonary malignancies, which is linked to its susceptibility 
to inflammatory insults (13, 16, 38). However, the molecular mech-
anism of such metastatic vulnerability remains largely elusive. Herein, 
Fig. 5. CM from B16F10 cells induces neutrophil accumulation in the lung microenvironment. (A) Schematic diagram showing the schedule for B16F10-CM treat-
ment. WT and Del1KO mice (n = 8 each group) were intravenously administered with B16F10-CM for two consecutive days. Mice were euthanized the next day after the 
last B16F10-CM treatment. (B and C) Representative (B) and quantitative (C) flow cytometric analysis of myeloid cells and lymphocytes, graphed on Ly6C by Ly6G and CD3 
by NK1.1 dot plots, respectively, among CD45+ cell populations in the lungs depicted in (A). (D and E) Representative (D) and quantitative (E) flow cytometric analysis of 
myeloid cells, graphed on Ly6C by Ly6G dot plots, among CD45+ cell populations in the spleens depicted in (A). (F and G) Representative images (F) and quantification 
(G) of lung metastasis in WT or Del1KO mice (n = 7 each group) after administration of media or B16F10-CM as depicted in (A) and then injection of B16F10-Luc2 cells by 
luciferase-based bioluminescence imaging (BLI). One day after the last B16F10-CM treatment, mice received an intravenous injection of B16F10-Luc2 cells. Horizontal bars 
indicate the means (C and E). *P < 0.05; **P < 0.01.
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we first demonstrated DEL-1, an exemplar of a local inflammatory 
regulator with prominent expression in the lung, as a critical regu-
lator of melanoma lung metastasis. DEL-1 restrains metastatic spread 
of malignant melanoma to the lung, but not primary tumor growth, 
through a significant effect on leukocyte recruitment, particularly 
by attenuating Ly6G+ neutrophils, and IL-17A expression by  T cells. 
We showed that depletion of Ly6G+ cells in such a context reverses 
the prometastatic effect of DEL-1 deficiency and IL-17A dysregula-
tion. A local, but not systemic, control of metastasis by DEL-1 was 
further supported by finding altered inflammatory infiltrates cen-
tered on neutrophils in the lung metastatic niche, but comparable 
metastatic seeding of melanoma and intrinsic function of systemic 
NK cells. Together with reciprocal regulation between DEL-1 and 
IL-17A and their correlation with neutrophil recruitment, these 
findings suggest that DEL-1 acts as a local gatekeeper protecting 
from lung inflammation and associated metastasis formation.
Neutrophils are among the “first responders” to be recruited to 
the lung to mediate an inflammatory response against infection or 
tissue damage and have also emerged as key contributors to the 
formation of the lung metastatic niche (13, 27, 28). Metastatic colo-
nization and progression are provoked by neutrophil-associated 
systemic as well as local lung inflammation (16, 38). Although cir-
culating neutrophils may exert antimetastatic cytotoxicity depend-
ing on the context (43), neutrophils in the tumor microenvironment 
are reported to undergo phenotypic changes and acquire the ability 
to promote metastasis, in part, by dampening the antitumor immunity 
provided by cytotoxic cells (29, 31, 44). In this study, DEL-1 defi-
ciency was associated with an elevation of prometastatic neutrophils 
in the metastasis-bearing lung, along with a decrease in antimeta-
static NK cells. This is reminiscent of the dependence of neutrophil 
recruitment on DEL-1 in different inflammatory pathologies but, as 
demonstrated here, in a tumor metastatic setting. Moreover, the 
Fig. 6. DEL-1 deficiency promotes neutrophil recruitment to perimetastatic foci in the lung. (A) Scheme of two-photon intravital imaging. DsRed-B16F10 cells were 
intravenously injected (day 0) and imaged at day 5 for GFP+ neutrophils and DsRed+ B16F10 cells. (B and C) Representative images (B) and quantification (C) of neutrophils 
around metastatic foci in the lungs of LysM-GFP/WT (n = 10) or LysM-GFP/Del1 KO mice (n = 7). Scale bar, 50 m. (D) Migration trajectories of neutrophils observed for 
15 min in a field of view. The starting point for each neutrophil was set to zero. Axis unit = m. (E to G) Quantification of neutrophil velocity (E), displacement (F), and 
meandering index (G) from intravital imaging. (H) Broad view of cleared lung tissue 5 days after DsRed-B16F10 cell injection. Scale bar, 300 m. (I) Counts of neutrophils 
within 50 m from the boundaries of metastatic foci. (J) The number of neutrophils inside the metastatic foci. *P < 0.05; ****P < 0.0001.
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finding of reduced metastasis in conjunction with restored NK 
cells via depletion of Ly6G+ cells suggests that DEL-1 primarily af-
fects prometastatic neutrophil accumulation in the lung metastatic 
niche. This notion was supported by the preferential accumulation 
of neutrophils among BMDCs in the DEL-1–deficient lungs follow-
ing CM challenge and treatment with GM-CSF and IL-6. While we 
demonstrated the dispensable role of DEL-1 in neutrophils and NK 
cells in our metastasis model, DEL-1 may also affect other leuko-
cytes linked to metastatic outcome. In this regard, it merits further 
investigation using DEL-1 conditional knockout mouse targeting 
specific cell types to confirm our results.
DEL-1 deficiency is causally linked to IL-17–mediated inflam-
matory pathologies, and infiltrating leukocytes are the main producers 
of IL-17 (11, 12). Supporting this, DEL-1 deficiency led to an eleva-
tion of IL-17A–producing  T cells in metastasis-bearing lungs. 
Expansion and polarization of prometastatic or protumorigenic neu-
trophils are driven by IL-17+  T cells (29, 33), which represent an 
important source of IL-17 in mucosal tissues including the lung (12, 33). 
Consistent with this, local IL-17A administration herein could reca-
pitulate in WT mice the increased accumulation of neutrophils and 
melanoma lung metastasis by DEL-1 deficiency. We found that 
Ly6G+ cell depletion led to a significant reduction in tumor-induced 
IL-17+  T cells, implying that prometastatic neutrophils support 
the generation of IL-17A–producing  T cells. Given previous studies 
showing that IL-17+  T cells promote neutrophil accumulation, 
we speculate that there exists a positive-feedback loop between IL-17+ 
 T cells and neutrophils in the process of metastatic progression, 
which could be interrupted by the local anti-inflammatory factor 
DEL-1. In this regard, further studies would be required to address 
the exact mechanisms underlying the relationship among DEL-1 
deficiency, neutrophil accumulation, IL-17+  T cells, and lung 
metastasis.
Distinct from the role of host endothelial DEL-1 in metastasis 
suppression as shown here, previous studies have centered on the 
tumor-intrinsic role of DEL-1 in primary tumor progression (17–19). 
As such, DEL-1, albeit to variable extent of expression in certain 
cancer cell lines and tumor tissues, was linked to tumor cell prolifer-
ation, survival, and invasion. On the basis of these findings, targeting 
of tumor-derived DEL-1 has been considered a potential therapeutic 
strategy to suppress tumor progression. However, using immuno-
competent syngeneic mouse models herein, we found that melanoma 
lung metastasis was facilitated by DEL-1 deficiency, pointing to an 
opposite function of host DEL-1 over tumor-intrinsic DEL-1. This 
speculation was further supported by an antimetastatic effect of 
Del-1-Fc administration. Thus, given the crucial role of the immune 
system in tumor progression and metastasis, caution would be re-
quired to consider DEL-1 as a target for cancer therapy, particularly 
in cases of primary or metastatic tissues with prominent endoge-
nous DEL-1 expression.
In summary, here, we demonstrate the previously unappreciated 
antimetastatic effect of DEL-1 on melanoma lung metastasis via 
limiting neutrophil accumulation beyond its defined role as a local 
inflammatory regulator in diverse inflammatory disorders. In this 
regard, it is tempting to speculate that DEL-1 could restrain the de-
velopment of pulmonary metastasis from other cancers. In support, 
we observed a similar aggravation of lung metastasis by DEL-1 de-
ficiency in a neutrophil-dependent manner using an experimental 
metastasis model of TC-1 lung cancer cells (fig. S14). To validate 
and extend our findings to other cancer types, further studies in a 
different lung metastasis model, including another model of meta-
static melanoma, will be required. One issue of great interest that 
remains to be addressed is the clinical relevance of the results in this 
study. In primary melanoma, neutrophil infiltration is associated 
with poor prognosis (45), whereas metastatic primary melanomas 
with a high NK score are linked to better patient survival (46). Given 
the neutrophil accumulation along with NK cell decrease as a fea-
ture of DEL-1–deficient metastatic lungs, it is our belief that DEL-1 
may affect the melanoma lung metastasis and patient prognosis. 
Thus, the relationship between lung-resident DEL-1 and melanoma 
metastatic outcome warrants further investigation. In addition to 
the lung, brain and bone, where functional expression of DEL-1 is 
demonstrated, are also major organs targeted by metastasis. Thus, 
studying the role of DEL-1 in the regulation of metastatic progres-
sion therein merits further investigation. In addition, investigation 
of other local inflammatory regulators that are potentially tailored 
to specific tissues in the context of tumor development and metas-
tasis formation will also be of interest.
MATERIALS AND METHODS
Study design
The objective of this study was to investigate the role of local tis-
sue-derived factor, DEL-1 herein, in the regulation of pulmonary 
metastasis, given the focus of previous studies on the components 
derived from primary tumor or recruited leukocytes to the meta-
static niche. The contribution of DEL-1 to melanoma lung metastasis 
was analyzed by both experimental and spontaneous models of 
metastasis using syngeneic immunocompetent mice and B16F10 
melanoma cells expressing DsRed that enable a quantitative assessment 
of metastatic spread. This approach was distinct from previous studies 
that are confined to the role of tumor cell–derived DEL-1 in promot-
ing their own proliferation and invasion, using an immunodeficient 
mouse model, without the assessment of tumor-host interactions. 
Lung and other tissues and host cells were obtained for the analyses 
of gene expression, fluorescent imaging, flow cytometry, (immuno)
histological staining, and intravital and 3D imaging. A series of 
in vivo and in vitro experiments allowed us to identify a significant 
role of DEL-1 in protection from melanoma lung metastasis via 
limiting the recruitment of prometastatic neutrophils in lung meta-
static niche, which was strengthened by the intravital and 3D imaging 
of neutrophils. A reasonable sample size was chosen to ensure 
adequate reproducibility of the results and to achieve statistical 
significance, which was based on our previous studies related to 
DEL-1. No animal data were excluded. Mice were assigned accord-
ing to their genotype. Age/sex-matched littermates were used when-
ever possible. In in vivo experiments, investigators were blinded 
to the genotype of the experimental groups. Mouse samples were 
labeled as numeric numbers and analyzed in a blinded manner. 
Biological and technical replicates have been performed. Most of 
the experiments have been reproduced two to three independent 
times with comparable results. The experimental findings, particularly 
DEL-1–mediated suppression of melanoma lung metastasis, have 
been reproduced with similar results from three independent labo-
ratories and are shown with representative data.
Mice
Del1KO mice on a C57BL/6 background (7) were provided by 
T. Chavakis (Dresden University, Germany). Six- to eight-week-old 
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littermates were used for tumor model experiments. C57BL/6 mice 
were purchased from Orient Bio (Seongnam, Korea). Animals were 
fed ad libitum and kept under specific pathogen–free conditions. 
All experimental protocols were approved by the Institutional Animal 
Care and Use Committee of the Asan Institute for Life Sciences. 
Del1 KO mice were crossed with mice heterozygous for GFP ex-
pressed under the lysozyme-M promoter (LysM-GFP) (40) to generate 
LysM-GFP/WT or LysM-GFP/Del1 KO mice. Six- to eight-week-old 
littermates were used for intravital imaging and tissue clearing. 
Mice were maintained in the Avison Biomedical Research Center 
(ABMRC) of Yonsei University College of Medicine. All experi-
mental protocols were approved by the Institutional Animal Care 
and Use Committee of the Yonsei University College of Medicine 
(IACUC No. 2019-0097).
Cell culture and reagents
B16F10 and B16F10-Luc2 melanoma cell lines [American Type 
Culture Collection (ATCC)] were cultured in Dulbecco’s modified 
Eagle’s medium (DMEM) supplemented with 10% fetal bovine serum 
(FBS) and harvested for tumor model experiments using Detachin 
Cell Detachment Solution (Gelantis). TC-1 lung cancer cell line was 
cultured in RPMI 1640 medium supplemented with 10% FBS and 
2 mM l-glutamine. YAC-1 (ATCC), RMA, and RMA-s murine 
lymphoma cell lines were cultured in RPMI 1640 medium supple-
mented with 5% FBS and 2 mM l-glutamine. P815 (ATCC) cell line 
was cultured in IMDM (Iscove’s Modified Dulbecco’s Medium) medium 
supplemented with 10% FBS and 2 mM l-glutamine. Plat-A retroviral 
packaging cell line (Cell Biolabs) was cultured in DMEM supplemented 
with 10% FBS, puromycin (1 g/ml), and blasticidin (10 g/ml). 
DsRed-tagged B16F10 cells were generated by transducing B16F10 
cells with DsRed retroviral construct (Addgene). Retroviral particles 
were produced by transfection of Plat-A retroviral packaging cell 
line with pMXs-DsRed Express. B16F10 cells were transduced with 
virus-containing supernatant by spinfection in the presence of poly-
brene (4 g/ml). Thereafter, B16F10 transductants showing DsRed 
expression were selected by fluorescence-activated cell sorting (FACS) 
and grown as pure cultures. DsRed-tagged TC-1 cells were generated 
by the same strategy as described for DsRed-B16F10 cells. Human 
Del-1-Fc fusion protein (Del-1-Fc) purified from human embryonic 
kidney 293 F cells (EDIL3-C-Fc) and control-Fc were purchased 
from Y-Biologics (Daejeon, Korea). Recombinant human IL-2 
was obtained from Roche; recombinant murine IL-17A was pur-
chased from PeproTech; recombinant murine GM-CSF and IL-6 
were obtained from R&D Systems; CFSE, CellTrace Far Red Cell 
Proliferation Kit, and LIVE/DEAD Fixable Green Dead Cell Stain 
were acquired from Molecular Probes; and XenoLight DiR NIR flu-
orescent dye was obtained from PerkinElmer.
Mouse tumor model
To generate models of primary tumor growth and spontaneous 
metastasis, 1 × 106 DsRed-tagged B16F10 cells in 100 l of Dulbecco’s 
phosphate-buffered saline (DPBS) were subcutaneously injected 
into the shaved flank of mice. Tumor volume was measured using 
digital calipers and calculated as V = (L × W2)/2. After 3 weeks of 
primary tumor growth, lung metastases were measured by ex vivo 
fluorescence imaging of excised lungs using the In Vivo Imaging 
System (IVIS) Lumina II (PerkinElmer) platform. For experimental 
metastasis, DsRed-tagged B16F10 cells or unlabeled B16F10 cells 
(2 × 105 or 5 × 105 cells) in 200 l of medium containing 5% FBS 
were injected into mice via the tail vein. Pulmonary metastases 
were assessed by histologic, gene expression profile, flow cytomet-
ric, and fluorescence imaging analyses on day 7 or 14 after tumor 
cell injection. For experiments monitoring extravasation and seed-
ing, B16F10 cells were incubated with XenoLight DiR dye (320 g/ml 
in DPBS) for 30 min at 30°C. Then, 5 × 105 cells were injected 
into mice via the tail vein, and initial seeding in lungs, livers, and 
spleens collected 30 min to 24 hours afterward was assessed by de-
tecting XenoLight DiR–positive tumor cells using an IVIS Lumina 
II system.
Depletion of NK cells, T cells, and neutrophils
To deplete NK cells, mice received intraperitoneal injections of 
10 l of rabbit anti–asialo-GM1 (Cedarlane Laboratories Ltd.) while 
the control mice were injected with rabbit serum (Sigma-Aldrich). 
The injections were performed 1 day before an intravenous injec-
tion of B16F10 cells and then twice a week until euthanasia. To de-
plete CD4+ or CD8+ T cells, mice were intraperitoneally injected 
with anti-CD4 (150 g per mouse, clone GK1.5; Bio X Cell) or 
anti-CD8 antibody (150 g per mouse, clone 2.43; Bio X Cell) 1 day 
before an intravenous injection of B16F10 cells, and then twice a 
week thereafter. Matching isotype rat IgG2b (clone LTF-2; Bio X Cell) 
was used as a control. To deplete neutrophils, mice were intraperi-
toneally injected with anti-Ly6G antibody (150 g per mouse, clone 
1A8; Bio X Cell) 1 day before an intravenous inoculation of B16F10 
cells, and then thrice a week thereafter. Matching isotype rat immuno-
globulin G2a (IgG2a) (clone 2A3; Bio X Cell) was used as a control. 
The depletion of NK cells, CD4 and CD8 T cells, and neutrophils 
was confirmed by flow cytometry.
NK cell–mediated lymphoma clearance assay
To assess whether DEL-1 deficiency affects systemic NK cell activity 
in vivo, a lymphoma clearance assay was performed as previously 
described (24). Briefly, lymphoma cells expressing MHC class I (RMA) 
or defective MHC class I (RMA-s) were labeled with 1 and 4 M 
CFSE, respectively. The cells were mixed in a 1:1 ratio (1 × 106 cells 
per each cell type) and injected intraperitoneally into WT or Del1KO 
mice. After the 6-hour challenge of RMA:RMA-s cells, the rejection of 
NK cell–sensitive RMA-s relative to NK cell–resistant RMA cells in 
the peritoneal cavity was measured using flow cytometry and 
calculated as follows: 1 − ([CFSElow/CFSEhigh]input/[CFSElow/CFSEhigh]
output) × 100%.
NK cell and CD8+ T cell degranulation assay
Cytotoxic degranulation was assessed by measuring cell surface ex-
pression of CD107a as previously described (47). Resting or IL-2–
activated NK cells isolated from splenocytes by negative selection using 
a mouse NK cell isolation kit (STEMCELL Technologies) were 
stimulated with YAC-1 or B16F10 cells for 4 hours. Lymphocytes were 
gated on forward scatter/side scatter, and the CD107a expression of 
CD3−NKp46+ NK cells was analyzed by flow cytometry. NK cell 
degranulation was determined by the percent increase of CD107a+ 
NK cells after stimulation with YAC-1 or B16F10 cells relative to 
CD107a+ NK cells without stimulation (CD107a+ cells). For assess-
ing CD8+ T cell-cytotoxic activity, IL-2–activated CD8+ T cells were 
isolated from splenocytes by negative selection using a mouse CD8+ 
T cell isolation kit (STEMCELL Technologies) and were stimulated 
with P815 cells preincubated with anti-CD3 antibody (10 g/ml, 
clone 145-2C11; BioLegend) or isotype control antibody (10 g/ml, 
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clone HTK888; BioLegend) for 4  hours. P815 cells are FcR+ and 
serve as a classical target for T cell cytotoxicity via their ability to 
bind antibodies to specific activating receptors (for example, CD3). 
In doing so, they can stimulate T cells through CD3. Cytotoxic 
degranulation was measured by surface expression of CD107a on 
CD3+CD8a+ T cells after lymphocyte gate.
Flow cytometry and intracellular staining
Lungs were perfused and removed from euthanized mice. Then, single- 
cell suspensions were obtained by incubating chopped tissues with col-
lagenase II (1 mg/ml) (Sigma-Aldrich), collagenase IV (Worthington), 
and deoxyribonuclease I (50 U/ml) (Roche) for 30 min at 37°C using 
a gentleMACS Octo Dissociator (Miltenyi Biotec). Isolated cells were 
washed, treated with red blood cells lysis buffer (eBioscience), and 
filtered through a 70-m strainer. Cell suspensions were preblocked 
with mouse BD Fc Block (clone 2.4G2), incubated with LIVE/DEAD 
Fixable Aqua Dead Cell Stain (Molecular Probes), and then incubated 
with conjugated antibodies. For intracellular staining of IL-17A, cell 
suspensions were stimulated with phorbol 12-myristate 13-acetate 
(20 ng/ml; Sigma-Aldrich), ionomycin (1 g/ml; Sigma-Aldrich), and 
GolgiPlug (BD Biosciences) for 3 hours at 37°C, followed by staining 
for surface markers. Cells were then fixed, permeabilized, and stained 
for IL-17A. The following antibodies were used for staining: anti–
CD45-eFluor 780 (clone 30-F11), anti–CD11b-PE (phycoerythrin)–Cy7 
(clone M1/70), anti–Ly6G- PerCP-Cy5.5 (clone 1A8), anti–Ly6C-APC 
(allophycocyanin) (clone AL-21), anti–F4/80-FITC (fluorescein 
isothiocyanate) (clone BM8), anti–CD11c-PE (clone HL3), anti–MHC 
II-PerCP-Cy5.5 (clone M5/114.15.2), anti–CD206-APC (clone C068C2), 
anti–CD3- PerCP (clone 145-2C11), anti–NK1.1-PE (clone PK136), 
anti–CD27-FITC (clone LG.7F9), anti–CD4-APC (clone RM4-5), 
anti–CD8a-PE (clone 53-6.7), anti–TCR-FITC (clone GL3), anti–
IL-17A-PE-Cy7 (clone eBio17B7), anti–NKp46-PE (clone 29A1.4), 
anti–CD107a-FITC (clone 1D4B), and anti–MHC I-PE (clone AF6-88.5). 
Labeled cell populations were measured using a BD FACSCanto 
II (BD Biosciences), and data were analyzed using FlowJo version 
10 (Tree Star). To analyze the survival of DsRed-tagged B16F10 
cells during lung metastasis formation, single-cell suspensions 
(2 × 105 cells) in the metastasis- bearing lungs of WT and Del1KO 
mice were stained with LIVE/DEAD Fixable Green Dead Cell Stain 
at room temperature (RT) for 30 min. B16F10 cells were gated on 
forward scatter/side scatter, and the LIVE/DEAD-stained dead 
cells of total DsRed-positive B16F10 cells were analyzed by flow 
cytometry.
NK cell cytotoxicity assay
To assess NK cell cytotoxicity in the metastasis-bearing lungs of 
WT and Del1KO mice, CellTrace Far Red-labeled B16F10 cells 
(1 × 104 cells) were cocultured with lung single cells (1 × 105 cells) 
for 6 hours at 37°C in the 96-well V bottom plate (Nunc). For the 
spontaneous death control, CellTrace Far Red-labeled B16F10 cells 
were cultured alone under the same conditions. Thereafter, cells 
were stained with the LIVE/DEAD Fixable Green Dead Cell Stain at 
RT for 30 min. B16F10 cells were gated on forward scatter/side scatter, 
and the LIVE/DEAD stain–positive dead cells among Far Red–labeled 
B16F10 cells were analyzed by flow cytometry.
In vitro myelopoiesis assay
Bone marrow cells were harvested from femurs and tibia of WT and 
Del1KO mice under sterile conditions. Cells were filtered through a 
70-m strainer and cultured in 24-well plates (5 × 105 cells per well) for 
4 days in RPMI 1640 medium supplemented with 10% FBS, 10 mM Hepes, 
and 50 M 2-mercaptoethanol. Recombinant GM-CSF (10 ng/ml) 
and IL-6 (10 ng/ml) were added in the cultures. Treatment media 
were changed every other day. On day 4, the frequency of different 
myeloid cells was analyzed by flow cytometry.
In vivo GM-CSF and IL-6 administration
To assess the effects of GM-CSF and IL-6 on the mobilization of 
myeloid cells, WT and Del1KO mice were intraperitoneally injected 
with recombinant GM-CSF (20 g/kg) and IL-6 (20 g/kg) daily for 
three consecutive days. After 4 days, mice were euthanized, and the 
cells from bone marrow, blood, or lung tissue were harvested for 
flow cytometry analysis of different myeloid cells.
RT2 Profiler PCR Arrays
Metastatic lung tissues were excised and placed immediately into 
RNAlater solution (Invitrogen) for RNA extraction. Thereafter, total 
RNA was isolated from the lung tissue using an RNeasy Microarray 
Tissue Mini Kit (Qiagen). As previously described (48), quantitative 
reverse transcription (RT)–PCR was used to measure the relative 
amounts of 84 different mRNAs in the lung tissue by using mouse 
Cancer Inflammation and Immunity Crosstalk RT2 Profiler PCR 
Arrays (Qiagen/SA Biosciences). cDNA was synthesized from 2 g 
of total RNA using SuperScript III reverse transcriptase (Invitrogen). 
Then, RT-PCR was performed using SuperArray Master Mix (Qiagen) 
and a Roche LightCycler 480 instrument, according to the manu-
facturer’s instructions. Experiments were performed on RNA pooled 
from three to four individual mice per group.
Quantitative RT-PCR
Real-time RT-PCR was performed in metastatic lung tissues isolated 
from WT mice or mice injected with B16F10 cells. Total RNA was 
isolated using QIAzol (Qiagen), and cDNA was synthesized using 
the High-Capacity cDNA RT Kit (Applied Biosystems/Thermo Fisher 
Scientific). The cDNA was amplified using LightCycler 480 SYBR 
Green 1 master in a LightCycler 480 machine (Roche). The following 
PCR conditions were used: 95°C for 15 min; 45 cycles of 30 s at 
95°C, 30 s at 60°C, and 30 s at 72°C; and 95°C for 15 min. Melting 
curve analysis was conducted for all PCR products to ensure primer 
specificity. DEL-1 mRNA levels were normalized to 18S mRNA levels, 
and relative transcript levels were determined using the compara-
tive CT method. Sequences of the primer used are as follows: DEL-1 
forward primer: 5′-CTT GGT AGC AGC CTG GCT TT-3′; DEL-1 
reverse primer: 5′-GCC TTC TGG ACA CTC ACA GG-3′; 18S for-
ward primer: 5′-CGC GGT TCT ATT TTG TTG GT-3′; and 18S 
reverse primer: 5′-AGT CGG CAT CGT TTA TGG TC-3′.
Histologic analysis and immunohistochemistry
To analyze metastatic foci formation in the lungs, the mice were 
euthanized, and the lung was fixed in Fekete’s solution. The meta-
static foci were assessed using a dissecting microscope (Nikon). The 
lung was also fixed with 4% paraformaldehyde, dehydrated, and then 
embedded in paraffin. Serial paraffin-embedded sections (4 m) 
were stained with hematoxylin and eosin (H&E). Slides after H&E 
staining were scanned with the Vectra slide scanner (PerkinElmer) 
to quantify the metastatic area, and the spectral library of hematoxylin 
was created. Then, inForm image analysis software (PerkinElmer) 
was applied to quantify the spectra in the lung tissues. To detect 
Hyun et al., Sci. Adv. 2020; 6 : eabc4882     6 November 2020
S C I E N C E  A D V A N C E S  |  R E S E A R C H  A R T I C L E
12 of 14
Ly6G+ neutrophils in the metastatic lungs, frozen sections (12 m) 
were incubated with primary antibody against Ly6G (1:100, 1A8; 
BD Biosciences) for 1 hour and stained using a Vectastain ABC kit 
(peroxidase, rat IgG; Vector Laboratories). The diaminobenzidine 
(DAB) signal was observed using the DAB substrate kit (Roche) and 
then imaged with a DM IL microscope (Leica).
Immunofluorescence
To detect neutrophils and NK cells in the metastatic lungs, serial 
frozen sections (12 m) were prepared and incubated with primary 
antibodies against Ly6G (1:100, 1A8; BD Biosciences) and NK1.1 
(1:100, PK136; BD Biosciences) for 1 hour followed by Alexa Fluor 
488–conjugated goat anti-rat F(ab′)2 (1:250; Jackson ImmunoResearch) 
and Alexa Fluor 647–conjugated goat anti-mouse F(ab′)2 (1:250; 
Jackson ImmunoResearch) for 30 min in PBS containing 1% bovine 
serum albumin and 1% goat serum. All incubations were performed 
under coverslips at RT, followed by three washes with PBS. Nuclei 
were stained with 4′,6-diamidino-2-phenylindole (DAPI) (Molecular 
Probes), and coverslips were mounted with ProLong Gold Antifade 
Reagent (Molecular Probes). Cells were imaged with an LSM 710 
laser-scanning confocal microscope (Carl Zeiss). To analyze DEL-1 
expression by endothelial cells in the metastatic lungs, frozen sec-
tions (15 m) were prepared, permeabilized with 0.1% Triton 
X-100 in PBS, and incubated with rabbit anti-mouse DEL-1 (1:200; 
AbFrontier) and Alexa Fluor 594–conjugated anti-mouse CD31 
(1:200, MEC13,3; BioLegend) for 12 hours at 4°C, followed by Alexa 
Fluor 488–conjugated goat anti-rabbit IgG (1:500; Invitrogen) for 
1 hour. Coverslips were mounted with Fluoromount-G (Electron 
Microscopy Sciences) after DAPI staining and then imaged with an 
LSM 710 confocal microscope. Regions of interest were randomly 
selected from the areas surrounding tumor foci. Protein expression 
was semiquantified from all images taken with the same settings after 
adjustments (exposure time, signal amplification, and objectives), 
using ImageJ software (NIH). To detect proliferation of B16F10 cells 
expressing DsRed in the metastasis-bearing lungs, serial frozen sec-
tions (15 m) were prepared and incubated with primary antibody 
specific for Ki67 (1:500, ab15580; Abcam), followed by Alexa Fluor 
488–conjugated goat anti-rabbit IgG (1:500; Invitrogen). Nuclei were 
stained with DAPI (Invitrogen). Proliferating B16F10 cells were iden-
tified as DsRed+Ki67+ cells. To detect apoptotic B16F10 cells ex-
pressing DsRed in the metastasis-bearing lungs, the frozen sections 
were subjected to terminal deoxynucleotidyl transferase–mediated 
deoxyuridine triphosphate nick end labeling (TUNEL) assay using 
a DeadEnd Fluorometric TUNEL System kit (Promega) according 
to the manufacturer’s protocol. TUNEL-positive B16F10 cells were 
imaged with an LSM 710 laser-scanning confocal microscope.
In vitro proliferation and apoptosis assay
To assess the effect of DEL-1 on the proliferation of B16F10 cells, 
CFSE-labeled B16F10 cells were treated with control-Fc or Del-1-Fc 
(100 nM) for 48 hours and then subjected to flow cytometric analysis 
of cell division by dilution of CFSE. To assess the effect of DEL-1 on 
cell viability, B16F10 cells were treated with control-Fc or Del-1-Fc 
(100 nM) for 3 days, stained with propidium iodide and fluorochrome- 
conjugated annexin V, and then analyzed by flow cytometry.
Conditioned media assay
CM was prepared from B16F10 cells (5 × 106 cells) cultured in 
serum-free DMEM in 10-cm plates (Nunc) for 24 hours. Harvested 
CM was centrifuged and filtered (0.22-m filter, Millipore) to re-
move cell debris. To study BMDC lung infiltration, CM (300 l) was 
injected intravenously into WT or Del1KO mice for two consecu-
tive days, and lungs were harvested the next day for flow cytometry 
analysis. To assess the effect of CM on melanoma lung metastasis, 
WT or Del1KO mice were treated with CM as described above and 
then subjected to tail vein injection of luciferase-tagged B16F10-
Luc2 cells (5 × 105 cells) on the next day. Pulmonary metastases 
were assessed on day 14 after tumor cell injection using biolumines-
cent imaging (IVIS Lumina II system). Luminescence was normalized 
to day 0 for each individual mouse to account for any differences in 
injection efficiency of B16F10 cells between mice.
Neutrophil adhesion and transmigration assays
Adhesion of mouse neutrophils isolated from bone marrow onto 
isolated and cultured mouse vascular lung endothelial cells was per-
formed as previously described (7). Briefly, purified and cultured 
lung endothelial cells from Del1KO mice were incubated in a micro-
titer plate (Nunc) until confluence. Fluorescence (BCECF)-labeled 
WT or Del1KO neutrophils (1 × 105 cells per well) were plated onto 
the endothelial cell monolayer and incubated at 37°C for 30 min. 
Following incubation periods and washing, the fluorescence of 
input and adherent cells was determined using a fluorescence plate 
reader (BioTek, Synergy HT). To assess transmigration of neutro-
phils through endothelial cells, primary endothelial cells were 
plated onto transwell culture inserts (SPL Life Sciences, 8-m pore 
size) and incubated until confluence. WT or Del1KO neutrophils 
(1 × 105 cells per well) were added to the upper chamber. The lower 
chamber contained serum-free medium and recombinant IL-8 
(5 ng/ml; R&D systems). After incubation for 50 min, the cells in 
the lower chamber were harvested and analyzed using LUNA-II 
Automated Cell Counter (Logos Biosystems Inc., Korea).
Two-photon intravital imaging
Two-photon intravital imaging was performed to observe neutro-
phil migration and melanoma tumor metastasis in the lung. For 
imaging, LSM 7MP microscope (Carl Zeiss Microscopy, Jena, 
Germany) equipped with a two-photon laser (690 to 1040 nm, 
MaiTai HD DeepSee tunable laser) was used. Morphology and mo-
tility of neutrophils were assessed at 880-nm wavelength in LysM- 
GFP/WT or LysM-GFP/Del1KO mice intravenously injected with 
DsRed-tagged B16F10 cells. Neutrophils (bright green) and mono-
cytes (dim green) were readily distinguishable due to their distinct 
brightness levels and morphological features (49). To induce meta-
static foci in the lung, 3 × 106 DsRed-B16F10 cells in 100 l of PBS 
were intravenously injected 5 days before imaging. To compare the 
extravasation of WT and Del1KO neutrophils through Del1KO 
vascular endothelial cells, neutrophils were prepared from WT or 
Del1KO mice using mouse neutrophil enrichment kit (STEMCELL 
Technologies, Vancouver, Canada). Thereafter, WT and Del1KO neutro-
phils were labeled with CellTracker CMTPX (red) and CellTracker 
CMFDA (green) (Thermo Fisher Scientific, Waltham, MA, USA), 
respectively, or vice versa. The labeled neutrophils were mixed 
in a 1:1 ratio (3 × 106 cells per each genotype) and injected intra-
venously into Del1KO mice 5 days after inoculation of 3  ×  106 
B16F10 cells. Then, two-photon intravital imaging was performed 
to count the WT and Del1KO neutrophils recruited to the metastasis- 
bearing lung of Del1 KO mice. For visualizing blood flow, Texas 
Red- dextran (70 kDa; Thermo Fisher Scientific, Waltham, MA, USA) 
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was intravenously injected. Lung imaging was performed via a 
thoracotomy of anesthetized mice, as previously described (50). 
Anesthesia was performed using Zoletil-Rompun mixture diluted 
1:10 in PBS before surgery.
Tissue clearing
Mice intravenously injected with DsRed-B16F10 cells were euthanized 
with Zoletil-Rompun mixture. Before cardiac perfusion, fluorescence- 
conjugated Lycopersicon esculentum lectin (BioActs, Korea) was in-
jected to label blood vessels. Mice were perfused with PBS and 4% 
formaldehyde via the myocardium, and lungs were isolated. The lungs 
were then incubated in 4% formaldehyde for 24 hours at 4°C. Tissue 
clearing was performed to acquire 3D structural images using a Binaree 
Tissue Clearing Kit (Binaree, Korea) according to the manufacturer’s 
instructions. For counts of neutrophils within 50 m from the 
boundaries of metastatic foci, metastatic foci with similar size to be 
analyzed were randomly selected in 3D. Then, three cross sections 
for each selected focus were randomly chosen in 2D, and neutrophils 
within 50 m of these metastatic foci were counted. For counts of 
neutrophils inside the metastatic foci, three metastatic foci with similar 
size were arbitrarily chosen. Each selected focus was volumized us-
ing software, and the colocalized neutrophils were counted.
Imaging data analysis
Intravital imaging data were obtained and analyzed using Volocity 
(PerkinElmer, MA, USA, Waltham, USA), Imaris (BITPlan, Switzerland), 
and Fiji (NIH) software. All data are expressed as the mean ± SEM.
Statistical analysis
Data were analyzed with GraphPad Prism software version 5 
(GraphPad Software). Two groups were compared using Student’s 
t test. Comparisons of more than two groups were analyzed by one-
way analysis of variance (ANOVA) followed by Dunnett’s multiple 
comparisons test. Data are expressed as mean ± SEM for in vivo 
mouse tumor model. Statistical significance was defined as P < 0.05.
SUPPLEMENTARY MATERIALS
Supplementary material for this article is available at http://advances.sciencemag.org/cgi/
content/full/6/45/eabc4882/DC1
View/request a protocol for this paper from Bio-protocol.
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